SUTRO BIOPHARMA INC. - COMMON STOCK

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

21 11月 2023 16:05:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

13 11月 2023 16:30:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

22 10月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

16 10月 2023 16:05:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

19 9月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

30 8月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

10 8月 2023 16:30:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

26 6月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

03 6月 2023 16:00:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

31 5月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

15 5月 2023 08:00:01 条件 Nasdaq GlobeNewswire

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

08 5月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

27 4月 2023 16:30:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

18 4月 2023 13:30:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

30 3月 2023 16:30:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 3月 2023 16:01:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference

01 3月 2023 08:00:01 条件 Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer  

28 2月 2023 08:00:03 条件 Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 2月 2023 16:01:00 条件 Nasdaq GlobeNewswire

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer

09 1月 2023 16:05:00 条件 Nasdaq GlobeNewswire